Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study
British Journal of Dermatology · 23.10.2026
DOI: 10.1093/bjd/ljag475 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 23.10.2026. Verfasst von Peyton V Warp und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
In this retrospective cohort study of 202 patients at the University of Miami, we assessed whether treatment lapses influence outcomes in early-stage mycosis fungoides. We found that patients who had treatment lapses were more likely to experience worsening of their disease and transformation to a more aggressive form. These findings suggest that continuity of treatment, even with low-intensity regimens, may be important for long-term disease control.
Autor:innen und Institutionen
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
- University of Miami Miller School of Medicine, Miami, Florida, USA.
ORCID-Profile: Peyton V Warp
Zitieren
APA
Warp, P. V., Tordjman, L., Cohen, R., & Elman, S. A. (2026). Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag475
Vancouver
Warp PV, Tordjman L, Cohen R, Elman SA. Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag475
BibTeX
@article{Warp2026,
author = {Warp, Peyton V and Tordjman, Lea and Cohen, Rachel and Elman, Scott A},
title = {Treatment lapses impact early-stage mycosis fungoides outcomes: a 14-year retrospective cohort study},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag475}
}
EUVIMED